

Specialty Review in Neonatology

Topic: This educational course covers foundational and fundamental Neonatal-Perinatal Medicine, taught by expert matter educators, and serves the purpose for foundational patho-physiological understanding of Neonatal-Perinatal Medicine, as well as preparing attendees for certifying exams.

Date: 2/17/2020 – 2/22/2020

Location: San Diego, CA

Accreditation:

The MEDNAX Center for Research, Education, Quality and Safety is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The MEDNAX Center for Research, Education, Quality and Safety designates this Live Activity for a maximum of 47.0 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. (#PO258)

The MEDNAX Center for Research, Education, Quality and Safety designates this Live Activity for a maximum of 47.0 *nursing contact hour(s)*. Participants should only claim credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety designates this Live Activity for a maximum of 4.00 *pharmacotherapeutics contact hour(s)*.

Disclosure of Financial Relationships:

Disclosure of Financial Relationships and Resolution of Conflicts of Interest is designed to ensure quality, objective, balanced, and scientifically rigorous continuing education activities. All individuals in a position to influence and/or control the content of continuing education activities have been asked to disclose all relevant financial relationships within the past 12 months. Any real or apparent conflicts of interest related to the content of the faculty's presentation have been resolved as have any real or apparent conflicts of interest by the planners as related to the content of this conference. Beyond disclosure of relevant financial relationships, faculty are required to disclose when they plan to discuss pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical. The MEDNAX Center for Research, Education, Quality and Safety is committed to providing learners with commercially unbiased continuing education activities.

The planners, moderators or speakers of this activity have the following financial relationship(s) with commercial interests to disclose:

Laurie Armsby, MD, FAAP, FSCAI Disclosure(s) - I/we have no financial relationships to report. *FDA: dopamine, dobutamine, epinephrine, norepinephrine, and milrinone – off-label drugs discussed.*

Tandy Aye, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

Dara Brodsky, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: dopamine, dobutamine, epinephrine, norepinephrine, and milrinone – off-label drugs discussed.*

David J Burchfield, MD Disclosure(s) - I/we have no financial relationships to report.

Reese H Clark, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: H2 Blockers and Proton Pump Inhibitors (PPIs) - not approved by the FDA for use in neonates.*

Michael J. Gambello, MD, PhD Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

The planners, moderators or speakers of this activity have the following financial relationship(s) with commercial interests to disclose:

Lucky Jain, MD, MBA Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

Martin Keszler, MD Disclosure(s) - Consulting Fee-Draeger Medical, Inc, Lecture honoraria-Draeger Medical, Inc, Research grant-Mallinckrodt, Inc., Draeger Medical, Inc. *FDA: Nothing to disclose.*

Pedro Mancias, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

Camilia Martin, MD Disclosure(s) - Contracted Research-Alcresta Therapeutics, Contracted Research-Abbott Laboratories, Consulting Fee-Mead Johnson Nutrition, Scientific Advisory Board-Fresenius Kabi, Scientific Advisory Board-Prolacta Biosciences, Laurent *FDA: Nothing to disclose.*

James Moore, MD, PhD Disclosure(s) - Speakers Bureau-Chiesi USA *FDA: Nothing to disclose.*

Fernando Moya, MD Disclosure(s) - Consulting Fee-WindTree Therapeutics *FDA: Nothing to disclose.*

Ravi Patel, MD, MSc Disclosure(s) - Travel support to attend SIGNEC 2018 conference (UK)-Danone Nutricia *FDA: Nothing to disclose.*

Blake Porter, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

Matthew Saxonhouse, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: Off-label use of Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) for anticoagulation; Off-label use of Recombinant Tissue Plasminogen Activator (rTPA) in thrombolysis discussed.*

David Weisoly, DO Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

Michael Weiss, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

Jon Williams, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

James Wynn, MD Disclosure(s) - Consulting Fee-Fluid Imaging Technologies, Contracted Research-National Institutes of Health *FDA: Nothing to disclose.*

John Zupancic, MD Disclosure(s) - I/we have no financial relationships to report. *FDA: Nothing to disclose.*

Hilja Dodd Sousa Conceicao, CHCP, CPHQ Disclosure(s) - I/we have no financial relationships to report.

Kassandra S Greci, DNP, APRN, WHNP-BC Disclosure(s) - I/we have no financial relationships to report.

Commercial Support:

There is no commercial support for this activity.

Purpose

The purpose of this educational activity is to provide an intensive and comprehensive review of neonatal medicine.

Objectives: At the conclusion of this activity, the participant will be able to:

ACCME Objective

1. Extensively discuss the pathophysiology of the mother and neonate.

Outcome - Participants will be able to identify one (or more) neonatal pathophysiologic, diagnostic or clinical management concept(s) to improve patient outcome.

CME – ACGME/ABMS Competencies addressed in this activity include medical knowledge.

ANCC Learning Outcomes

1. Discuss the pathophysiology of the mother and neonate.

2. Identify one (or more) neonatal pathophysiologic, diagnostic or clinical management concept(s) to improve patient outcome.

CNE – IOM Competencies: 1. Employ evidence-based practice

Evaluation, Attendance and Credit:

Within <https://mednax.cloud-cme.com>, click My CE and then select Evaluations and Certificates. Follow the instructions to record attendance/time spent and complete the brief evaluation. You will have the option to email the certificate of attendance to your mailbox.